although lithium was first discovered to be effective in mania in 1949, by the Melbourne psychiatrist John Cade, it is still the 'gold standard' therapy.
many patients are unable to tolerate lithium and it has limited effectiveness for the depressive phase of bipolar disorders.
many patients on lithium suffer from frequent and prolonged depressive episodes, despite dramatic suppression of the periods of elevated mood.
non-compliance is common (20-50% of patients) and if lithium is abruptly discontinued, the chance of sudden relapse into mania is considerable.
the main drawbacks of lithium are the need for serum concentration monitoring, the possibility of serious toxicity, and the risk of thyroid (and less commonly renal) impairment.
tremors, increased muscle tone, hyperreflexia and disorientation are signs of severe toxicity.